Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
British journal of clinical pharmacology（2023）
摘要
Dostarlimab does not cause clinically significant QTcF prolongation exceeding the regulatory concern threshold.
更多查看译文
关键词
cardiac arrhythmia,electrocardiogram QT prolonged,immune checkpoint inhibitors,monoclonal antibodies,risk factors,torsade de pointes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要